A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Sponsor:

SWOG

Sponsor Study ID:

21CTP.HN01

CTO #:

104286

NCT Number:

NCT07062354

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Larynx; Lip, Oral Cavity and Pharynx

Study Objectives:

To assess the overall response rate (ORR) (confirmed complete and partial responses per RECIST 1.1) of amivantamab hyaluronidase + carboplatin + paclitaxel in participants with platinum naive unresectable recurrent or metastatic head and neck squamous cell carcinoma previously treated with a PD-1 inhibitor.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)